 | |
- close
- close
|
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
WIKI ANALYSIS
Theravance, Inc. is a late-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecule medicines in the U.S. It develops medicines for respiratory diseases, bacterial infections, and gastrointestinal motility dysfunction. The company received an approvable letter from the U.S. Food and Drug Administration (FDA) for its lead bactericidal injectable antibiotic, Telavancin. Telavancin is being developed for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). The drug is also being investigated in a phase III trial for the treatment of hospital-acquired pneumonia. Phase II clinical trials for the company's next-generation heterodimer antibiotic, TD-1972, for the treatment of cSSSI caused by Gram-positive bacteria, including resistant pathogens such as MRSA, are also ongoing.
Theravance has collaboration arrangements with Astellas Pharma, Inc. for the development and commercialization of Telavancin GlaxoSmithKline to develop and commercialize long-acting beta2 agonist (LABA) product candidates for the treatment of asthma and chronic obstructive pulmonary diseases and AstraZeneca AB to develop and commercialize intravenous anesthetic compound. The company also has a strategic alliance with GlaxoSmithKline, under which the company has licensed one compound each under the long-acting muscarinic antagonist (LAMA) and the bifunctional muscarinic antagonist-beta2 agonist (MABA) programs. Theravance was founded in 1996 and is headquartered in South San Francisco, California. The company employed 285 employees at the end of 2006.
References
| ||||||
|
|
